CytoSeek's mission is to use Artificial Membrane Binding Protein technology to deliver the potential of the next generation of cell therapies, with a focus on treating solid tumours.
The company was founded in November 2017 to commercialise the technology developed by Professor Adam Perriman and his team at the University of Bristol.
CytoSeek is now engaged in proof of principle studies for multiple product candidates, and is seeking to enhance cell therapies against solid tumours.
We create technologies that drive human progress.
Our story began with a belief and a passion: that everybody should have easy access to the best technology anywhere in the world. That was in 1984 in Michael Dell’s University of Texas dorm room. Today, Dell Technologies is instrumental in changing the digital landscape the world over.
We are among the world’s leading technology companies helping to transform people’s lives with extraordinary capabilities. From hybrid cloud solutions to high-performance computing to ambitious social impact and sustainability initiatives, what we do impacts everyone, everywhere.
Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.
Sphere Fluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells